Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS

M. Magnani, A. Fraternale, A. Casabianca, G. F. Schiavano, L. Chiarantini, A. T. Palamara, M. R. Ciriolo, G. Rotilio, E. Garaci

Research output: Contribution to journalArticlepeer-review


A combination of antiretroviral drugs acting at different points in the virus replication cycle was evaluated in a murine retrovirus-induced immunodeficiency model of AIDS (MAIDS). Intramuscular administration of high doses of reduced glutathione (GSH, 100 mg/mouse/day) and AZT (0.25 mg/ml in drinking water) was found to reduce lymphoadenopathy (92%), splenomegaly (80%), and hypergammaglobulinemia (90%) significantly more than AZT alone. Combined treatment resulted in a reduction in proviral DNA content of 69, 66, and 60%, respectively, in lymph nodes, spleen, and bone marrow. Furthermore, the stimulation index of B cells was also significantly higher in animals receiving GSH and AZT whereas additional responses were not observed in the T cell stimulation index and blood lymphocyte phenotype analyses. In conclusion, the administration of high doses of GSH and AZT, a new combination of antiviral drugs, seems to provide additional advantages compared to single-agent therapy.

Original languageEnglish
Pages (from-to)1093-1099
Number of pages7
JournalAIDS Research and Human Retroviruses
Issue number13
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Immunology
  • Virology


Dive into the research topics of 'Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS'. Together they form a unique fingerprint.

Cite this